Biotimize
Piracicaba
About Biotimize
Biotimize is the first biologics Contract Development and Manufacturing Organization (CDMO) in Brazil. The company provides end-to-end solutions for the development and production of biopharmaceuticals, including monoclonal antibodies, biosimilars, vaccines, and advanced therapies. Biotimize’s mission is to maximize the development and production of biopharmaceuticals, making innovation accessible and economically viable so that transformative treatments reach those in need. With a strong technical team and state-of-the-art infrastructure under expansion, Biotimize addresses a critical gap in LATAM: the region’s heavy dependence on imported biopharmaceuticals. By enabling local and international companies to develop and manufacture products closer to patients, Biotimize strengthens health sovereignty, reduces costs, and accelerates access to life-saving therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $30.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: biotimize.com.br
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/biotimize-34714 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.